Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated unresectable or metastatic colorectal cancer
CTR20261212Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig, bevacizumab in colorectal cancer (CRC), sponsored by Bristol Myers Squibb. Started Sep 2026; status: active.
02
Drugs
pumitamigbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20261212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261212.